| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/08/2004 | WO2003053292B1 Vaginal delivery of drugs |
| 07/08/2004 | WO2003049685A3 Treatment for age-related macular degeneration |
| 07/08/2004 | WO2003042358A3 Methods of using 48149, a human aminopeptidase family member |
| 07/08/2004 | WO2003039553B1 Compositions for treatment of postmenopausal female sexual dysfunction |
| 07/08/2004 | WO2003032941A3 Cosmetic and/or dermatological active ingredient combination |
| 07/08/2004 | WO2003027233A3 Isolation and cultivation of microorganisms from natural environments and drug discovery based thereon |
| 07/08/2004 | WO2003026591A9 Modification of feeding behavior |
| 07/08/2004 | WO2003021225A3 Method for classification of anti-psychotic drugs |
| 07/08/2004 | WO2003002058A9 Bone anabolic compounds and methods of use |
| 07/08/2004 | WO2002097060A3 Carbohydrate-associated proteins |
| 07/08/2004 | US20040133356 Three-dimensional model of a Fc region of an IgE antibody and uses thereof |
| 07/08/2004 | US20040133155 Devices for intraocular drug delivery |
| 07/08/2004 | US20040132824 Novel methods and compositions for alleviating pain |
| 07/08/2004 | US20040132821 acetyl-L-carnitine and a mixture of polyphenols containing hydroxytyrosol; preventing tissue damage caused by free radicals, diabetic or toxic neuropathies and metabolic disorders of glucose utilization |
| 07/08/2004 | US20040132810 Odorless formulation for treating mucosal discontinuities |
| 07/08/2004 | US20040132807 Aurones as telomerase inhibitors |
| 07/08/2004 | US20040132805 preferably also contains a compound that donates, transfers, releases or induces production of nitric oxide and a hydralazine antioxidant; for treating and/or preventing a vascular disease characterized by nitric oxide insufficiency |
| 07/08/2004 | US20040132802 delaying release of a poorly water soluble statin, especially simvastatin and/or lovastatin, for a time sufficient to avoid exposure of said statin to the stomach, duodenum, and jejunum; and releasing said statin in the ileum, colon, or both |
| 07/08/2004 | US20040132797 treating of or preventing relapse of depression, anxiety disorders, eating disorders, or urinary incontinence |
| 07/08/2004 | US20040132781 Pyrazole compounds useful as protein kinase inhibitors |
| 07/08/2004 | US20040132780 Method and compositions for treating migraines |
| 07/08/2004 | US20040132771 solid amorphous adsorbate provides concentration enhancement of the CETP inhibitor resulting in improved bioavailability |
| 07/08/2004 | US20040132758 hyterocyclylaminomethyl- or aminocarbonyl-substituted 9,10-ethanoanthracenes or their aza derivatives; treating obesity, diabetes, inflammatory and immune disorders |
| 07/08/2004 | US20040132754 signal transduction inhibitor is a PDGF receptor tyrosine kinase inhibitor or an active ingredient which decreases the activity of the epidermal growth factor; antiproliferative agent |
| 07/08/2004 | US20040132739 e.g. RO 28-2653 in combination with Cisplatin, Paclitaxel, Gemcitabine or Etoposide; treating patients with solid metastasized or non-metastasized tumors |
| 07/08/2004 | US20040132737 especially dimethylphenylpiperazinium; treating a variety of pulmonary diseases with fewer side effects than other anti-inflammatory drugs, such as steroids |
| 07/08/2004 | US20040132731 Novel combination |
| 07/08/2004 | US20040132728 e.g., doxazosin or 5-cyclopropyl-7-methoxy-2-(2-morpholin-4-ylmethyl-7,8-dihydro[1,6]-naphthyridin-6(5H)-yl)-4(3H)quinazolinone; treatment of benign prostatic hyperplasia |
| 07/08/2004 | US20040132722 Glycoprotein-mediated MDR |
| 07/08/2004 | US20040132710 Lactams as tachkinin antagonists |
| 07/08/2004 | US20040132701 Steroid hormones, especially the oestrogens |
| 07/08/2004 | US20040132700 Use of fluticasone propionate in the treatment of diseases ameliorated by enhancement of epithelial madrix adhesion such as asthma cystic fibrosis and influenza |
| 07/08/2004 | US20040132689 Aqueous preparation containing a shark-derived chondroitin iron sulfate colloid |
| 07/08/2004 | US20040132685 Immunostimulatory nucleic acid |
| 07/08/2004 | US20040132643 Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms |
| 07/08/2004 | US20040132639 Dipeptidyl peptidaseIV and alanyl-aminopeptidase inhibitors |
| 07/08/2004 | US20040132636 Pharmaceutical uses for alpha2delta ligands |
| 07/08/2004 | US20040132179 Treatment of t cell disorders |
| 07/08/2004 | US20040132161 Methods and compositions for increasing CD4lymphocyte immune responsiveness |
| 07/08/2004 | US20040132159 Novel beta-secretase and modulation of beta-secretase activity |
| 07/08/2004 | US20040132115 Method for screening compounds for alpha1B adrenergic receptor antagonist and analgesic activity |
| 07/08/2004 | US20040132093 Comprises cytokine receptor fusion protein for use in indentifying modulators for treatment of bone disorders |
| 07/08/2004 | US20040132057 Tumor necrosis related receptor,TR7 |
| 07/08/2004 | US20040132053 Sphingosine kinase enzyme |
| 07/08/2004 | US20040132038 Membrane protein for use as diagnostic tool in the detection and prevention of cell proliferative, cardiovascular, skin, nervous system, respiratory and metabolic disorders |
| 07/08/2004 | US20040132021 Using presence of genetic variation in van buchem-sclerosteosis disease region to identify disorders resulting in either net excess bone formation or insufficient bone formation in humans; allelicvariation and bone disorders |
| 07/08/2004 | US20040131710 Methods for treating skin conditions |
| 07/08/2004 | US20040131707 an aqueous Soma, comprising apple cider vinegar, quinine, blackstrap molasses, sulfur, and whole milk; suited for treating lymphoid malignancies |
| 07/08/2004 | US20040131703 Antiinflammatory agents; respiratory system disorders |
| 07/08/2004 | US20040131701 Method to treat infectious diseases and/or to enhance antimicrobial efficacy of drugs |
| 07/08/2004 | US20040131696 Administering aluminum compound complexed to polyoxyalkylene glycol |
| 07/08/2004 | US20040131689 Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor |
| 07/08/2004 | US20040131687 Photokinetic delivery of biologically active substances using pulsed incoherent light |
| 07/08/2004 | US20040131676 Dosage forms containing a PPI, NSAID, and buffer |
| 07/08/2004 | US20040131667 Liposomal analgesic formulation and use |
| 07/08/2004 | US20040131665 Topical anesthetic formulation |
| 07/08/2004 | US20040131646 Gel delivery vehicles for anticellular proliferative agents |
| 07/08/2004 | US20040131644 Using phosphatides from poultry embryos |
| 07/08/2004 | US20040131643 Immune response potentiation |
| 07/08/2004 | US20040131631 Polyphosphazene immunostimulants |
| 07/08/2004 | US20040131629 Viricides: aids therapy |
| 07/08/2004 | US20040131626 Administering a genetic engineered polypeptide |
| 07/08/2004 | US20040131616 Methods of inhibiting proliferative diseases |
| 07/08/2004 | US20040131611 Antitumor agents, anticancer agents; synergistic mixture |
| 07/08/2004 | US20040131608 Antibodies; suppression, therapy, prevention |
| 07/08/2004 | US20040131604 Methods for inhibiting viral replication in vivo |
| 07/08/2004 | US20040131601 Injection of bone marrow-derived cells and medium for angiogenesis |
| 07/08/2004 | US20040131594 Malaria therapy; using pox virus vectors; genetic engineering; antitumor agents |
| 07/08/2004 | US20040131590 Anticancer agents |
| 07/08/2004 | US20040131587 Administering mixture of dendritic cells, apoptosis or necrosis agents,chemattractants |
| 07/08/2004 | US20040131585 Identification and use og human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 07/08/2004 | US20040131564 Use of active ingredient combinations consisting of alpha-lipoic acid and dermatologically compatible substances that absorb light in the uv-a and or uv-b wavelength range(s) for producing cosmetic or dermatological preparations |
| 07/08/2004 | US20040131563 Therapy for pigmenting diseases; skin disorders |
| 07/08/2004 | DE10259646A1 Promoting therapy of parodontopathy, especially paradontitis, by topical application of mometasone furoate to teeth or interdental spaces |
| 07/08/2004 | DE10259619A1 Verwendung einer TRPM8 aktivierenden Substanz zur Tumorbehandlung Using a TRPM8-activating substance for tumor treatment |
| 07/08/2004 | DE10259509A1 Product used for reducing weight, e.g. for producing satiating effect, comprises swellable compound that provides delayed release of nutriments and/or active agents in stomach and intestine |
| 07/08/2004 | DE10259506A1 Appetite-and cholesterol-reducing agent comprises a low esterified polysaccharide and a different material which is swellable |
| 07/08/2004 | DE10257478A1 Composition containing antioxidants and micronutrients, useful for treatment or prevention of paradontitis and associated disorders, also osteoporosis |
| 07/08/2004 | CA2551169A1 Organ preconditioning, arrest, protection preservation and recovery (2) |
| 07/08/2004 | CA2511202A1 Cyclopentil-substituted glutaramide compounds as endopeptidase inhibitors |
| 07/08/2004 | CA2510924A1 Methods for identifying therapeutic agents of atherosclerotic plaque lesions |
| 07/08/2004 | CA2510711A1 Novel aminobenzophenone compounds |
| 07/08/2004 | CA2510458A1 Compositions of cholesteryl ester transfer protein inhibitors and hmg-coa reductase inhibitors |
| 07/08/2004 | CA2510445A1 Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents |
| 07/08/2004 | CA2510019A1 Process for preparing combination pharmaceutical formulations using supercritical fluids |
| 07/08/2004 | CA2509688A1 Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
| 07/08/2004 | CA2509382A1 Stimuli-responsive systems for controlled drug delivery |
| 07/08/2004 | CA2508269A1 Methods and dosage forms for reducing heart attacks in a hypertensive individual with a diuretic or a diuretic and an ace inhibitor combination |
| 07/07/2004 | EP1435237A1 Prevention of migraine recurrence |
| 07/07/2004 | EP1435232A1 Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds |
| 07/07/2004 | EP1434991A2 New potent, selective and non toxic c-kit inhibitors |
| 07/07/2004 | EP1434990A2 Method for identifying compounds the specifically deplete mast cells |
| 07/07/2004 | EP1434886A2 Mid 241 receptor, a novel g-protein coupled receptor |
| 07/07/2004 | EP1434885A2 21132, a human g-protein coupled receptor family member and uses therefor |
| 07/07/2004 | EP1434876A1 Expression profiling in the intact human heart |
| 07/07/2004 | EP1434866A2 Genes associated with mast cell activation |
| 07/07/2004 | EP1434865A2 Variants and exons of the glyt1 transporter |
| 07/07/2004 | EP1434863A1 IDENTIFICATION AND USE OF MAMMALIAN p21 INHIBITORS |
| 07/07/2004 | EP1434860A2 Enzymes |
| 07/07/2004 | EP1434796A2 Secreted proteins |